A detailed history of Morgan Stanley transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Morgan Stanley holds 68,437 shares of BLRX stock, worth $31,481. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,437
Previous 291,354 76.51%
Holding current value
$31,481
Previous $326,000 88.04%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.56 - $0.86 $124,833 - $191,708
-222,917 Reduced 76.51%
68,437 $39,000
Q1 2024

Aug 16, 2024

BUY
$1.03 - $1.56 $54,685 - $82,825
53,093 Added 22.28%
291,354 $326,000
Q1 2024

May 15, 2024

BUY
$1.03 - $1.56 $54,685 - $82,825
53,093 Added 22.28%
291,354 $326,000
Q4 2023

Aug 16, 2024

BUY
$1.31 - $1.86 $222,469 - $315,872
169,824 Added 248.15%
238,261 $374,000
Q4 2023

Feb 13, 2024

BUY
$1.31 - $1.86 $81,873 - $116,248
62,499 Added 35.56%
238,261 $374,000
Q3 2023

Nov 15, 2023

SELL
$1.23 - $2.45 $104,813 - $208,774
-85,214 Reduced 32.65%
175,762 $319,000
Q2 2023

Aug 14, 2023

BUY
$0.96 - $1.78 $3,901 - $7,233
4,064 Added 1.58%
260,976 $417,000
Q1 2023

May 15, 2023

BUY
$0.56 - $0.89 $2,217 - $3,524
3,960 Added 1.57%
256,912 $228,000
Q4 2022

Feb 14, 2023

SELL
$0.57 - $0.95 $5,475 - $9,126
-9,607 Reduced 3.66%
252,952 $149,000
Q3 2022

Nov 14, 2022

BUY
$0.88 - $1.91 $9,130 - $19,816
10,375 Added 4.11%
262,559 $243,000
Q2 2022

Oct 27, 2022

SELL
$1.06 - $1.82 $20,512 - $35,218
-19,351 Reduced 7.13%
252,184 $323,000
Q2 2022

Aug 15, 2022

SELL
$1.06 - $1.82 $20,512 - $35,218
-19,351 Reduced 7.13%
252,184 $323,000
Q1 2022

Oct 27, 2022

BUY
$1.46 - $2.18 $28,252 - $42,185
19,351 Added 7.67%
271,535 $464,000
Q1 2022

May 13, 2022

BUY
$1.46 - $2.18 $16,598 - $24,784
11,369 Added 4.37%
271,535 $464,000
Q4 2021

Feb 14, 2022

BUY
$1.98 - $3.06 $39,675 - $61,316
20,038 Added 8.34%
260,166 $531,000
Q3 2021

Nov 15, 2021

BUY
$2.65 - $3.35 $636,339 - $804,428
240,128 New
240,128 $660,000

Others Institutions Holding BLRX

About BioLineRx Ltd.


  • Ticker BLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,524,500
  • Market Cap $28.3M
  • Description
  • BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...
More about BLRX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.